Transcenta Group-B and EirGenix Reach Biopharmaceutical Manufacturing Collaboration Agreement
December 29, 2025
Source: drugdu
31
On December 29, Transcenta Holdings Group-B (06628) announced a strategic collaboration and non-exclusive technology licensing agreement with EirGenix. The agreement aims to advance integrated continuous flow manufacturing of biopharmaceuticals and improve global accessibility to affordable biopharmaceuticals. Under the agreement, the company will grant EirGenix a non-exclusive license to its highly integrated continuous flow bioprocess manufacturing (HiCB) platform and provide complete process documentation, core process technologies and experience, and regulatory support services. The company will receive a substantial upfront payment and milestone payments, and will be able to collect future royalties related to the commercialization of the licensed technology. This collaboration is expected to significantly reduce production costs, enabling patients worldwide to access high-quality, affordable biologics. EirGenix plans to use the HiCB platform for its biologics development programs and manufacturing operations, supporting CDMO customers seeking highly integrated continuous flow manufacturing solutions.
https://finance.eastmoney.com/a/202512293604195792.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Jinghong Medical Secures Series A Strategic Financing, Co-led by Venture Capital and Binhu Industrial Group with FTEC Capital as Exclusive Financial Advisor December 29, 2025
- Brazil to launch single-dose dengue vaccination program; Chinese companies help boost vaccine production capacity December 29, 2025
- China Biopharmaceutical’s innovative drug TQH3906 completes Phase II clinical trial. December 29, 2025
- Sinovac Biotech’s adsorbent tetanus vaccine officially launched December 29, 2025
- A blockbuster drug with a market value of 5 billion yuan has been approved for a new indication December 29, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
